Evidence map›Paper›PMID 41893178›Full record

ArticleJournal of functional biomaterials2026

LXW7 Peptide Modification of Acellular Liver Scaffolds Improves Endothelialization and Hemocompatibility in Bioengineered Liver.

Usha Yadav, Chandra J Yadav, Sadia Afrin, Jun-Yeong Lee, Jihad Kamel, Kyung-Mee Park

Abstract read
In one paragraph

Article in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Usha YadavCollege of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.ORCID 0000-0003-3706-1176
Chandra J YadavCollege of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.ORCID 0009-0009-0910-2103
Sadia AfrinCollege of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.ORCID 0009-0001-8476-2074
Jun-Yeong LeeCollege of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.ORCID 0009-0004-3798-1858
Jihad KamelCollege of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.
Kyung-Mee ParkCollege of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.ORCID 0000-0002-7165-6731

Funding

the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET); Ministry of Agriculture, Food and Rural Affairs (321027-5); and Korean Fund for Regenerative Medicine (KFRM) 22A0101L1-11
6 · The paper itself

Abstract

End-stage liver disease caused by advanced fibrosis and cirrhosis remains a major global burden, yet its treatment is limited by donor organ shortages. Bioengineered liver scaffolds offer a promising alternative, but their efficacy is often limited by thrombosis, insufficient vascularization, and poor graft integration due to inadequate endothelialization. To overcome these challenges, we employed LXW7 αvβ3 integrin targeting peptide with high endothelial cell specificity and low platelet affinity to enhance re-endothelialization and hemocompatibility of decellularized liver scaffold (DLS) and thereby improve hepatic integration and function. LXW7 was covalently conjugated to the decellularized rat liver scaffold via EDC/NHS-mediated carbodiimide coupling and subsequently reseeded with human umbilical vein endothelial cells (HUVECs) and cultured in a perfusion bioreactor to promote endothelialization. LXW7 immobilization significantly improved HUVECs attachment and proliferation, achieving approximately 81% vascular coverage, while sustaining the endothelial function. Ex vivo blood perfusion showed minimal thrombus formation and markedly reduced platelet adhesion, demonstrating enhanced hemocompatibility. Following confirmation of endothelialization, scaffolds were recellularized with hepatocellular carcinoma (HepG2) cells and HUVECs. LXW7 modified scaffolds promote organized hepatocyte distribution, sustained albumin expression, and increased urea secretion. In vivo implantation of LXW7-DLS into the omentum of mice promoted robust host endothelial recruitment and enhanced neovascularization, highlighting the scaffold's excellent biocompatibility and good integration with surrounding tissues. Moreover, in vivo implantation of LXW7 recellularized scaffolds into a thioacetamide-induced fibrotic mouse liver resulted in reduced collagen deposition and lowered serum ALT/AST levels, demonstrating hepatic regeneration and extracellular matrix remodeling. Overall, our results showed that LXW7-modified DLS promotes stable endothelialization, improves hemocompatibility, and enhances hepatic function, underscoring its translational potential for the development of vascularized transplantable liver grafts.

Indexed as

bioengineered liverendothelializationfibrosishemocompatibilityLXW7

Identifiers

PMID41893178
PMCPMC13027059

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.